ERBB2 and non-small cell lung carcinoma: Trastuzumab emtansine is an anti-HER2 antibody-drug conjugate that showed a signal of activity in patients with HER2 overexpressing advanced NSCLC [55], and a phase II basket trial evaluated the activity of trastuzumab emtansine in patients with HER2 mutated NSCLC with a high response rate [56].